Meeting
2016 ASCO Annual Meeting
Development and validation of genomic signature to predict ADT treatment failure.
Authors
Jeffrey Karnes
Mayo Clinic, Rochester, MN
Jeffrey Karnes , Hussam Al-Deen Ashab , Bruce J. Trock , Ashley Ross , Harrison Tsai , Jeffrey J. Tosoian , Mohammed Alshalalfa , Voleak Choeurng , Kasra Yousefi , Zaid Haddad , Firas Abdollah , Eric A. Klein , Paul L. Nguyen , Felix Yi-Chung Feng , Adam Dicker , Robert Benjamin Den , Elai Davicioni , Tamara L. Lotan , Edward M. Schaeffer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Genitourinary (Prostate) Cancer
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 34, 2016 (suppl; abstr 5018)
DOI
10.1200/JCO.2016.34.15_suppl.5018
Abstract #
5018
Poster Bd #
275
Abstract Disclosures
Similar Posters
Poster
2016 Genitourinary Cancers Symposium
Development and validation of an ADT resistance signature to predict adjuvant hormone treatment failure.
First Author: Jeffrey Karnes
Poster
2016 ASCO Annual Meeting
HSD3B1 and resistance to androgen deprivation therapy in prostate cancer.
First Author: Jason W.D. Hearn
Poster
2015 ASCO Annual Meeting
HSD3B1 and resistance to androgen deprivation therapy in prostate cancer.
First Author: Jason W.D. Hearn
Poster
2023 ASCO Genitourinary Cancers Symposium
Use of prostate cancer subtyping by gene expression to predict response to radiation and chemohormonal therapies.
First Author: Adam B Weiner